Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497721 | 0.95 | PNMT (0.48) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL4059189 | 0.90 | PNMT (0.54) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL27429983 | 0.90 | PNMT (0.52) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL6849876 | 0.89 | PNMT (0.50) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL5499370 | 0.88 | PNMT (0.42) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL8474155 | 0.87 | PNMT (0.51) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL4839271 | 0.87 | PNMT (0.51) | PNMTNPC1RAB9AHTR7HTR2B | |
| Methyl Alcohol SCHEMBL7565244 | 0.87 | PNMT (0.41) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL1830397 | 0.87 | PNMT (0.57) | PNMTNPC1RAB9AHTR7HTR2B | |
| SCHEMBL4059193 | 0.86 | PNMT (0.50) | PNMTNPC1RAB9AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262169-B1 | Process for preparing peptide intermediates | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20030133927-A1 | Conjugates useful in the treatment of prostate cancer | DEFEO-JONES DEBORAH (US) | 2003-07-17 | — | — | US | disclosed |
| EP-1226158-B1 | PROCESS FOR PREPARING PEPTIDE INTERMEDIATES | MERCK SHARP & DOHME (GB) | 2003-07-02 | — | — | EP | disclosed |
| US-6552166-B1 | Oligopeptide is mixed with a salt of the anthracycline antibiotic in the presence of a carboxyl activating agent and a base | MERCK & CO., INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1228089-A2 | SALT FORM OF A CONJUGATE USEFUL IN THE TREATMENT OF PROSTATE CANCER | Merck & Co., Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1225918-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | Merck & Co., Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1226158-A1 | PROCESS FOR PREPARING PEPTIDE INTERMEDIATES | MERCK SHARP & DOHME LTD. (GB) | 2002-07-31 | — | — | EP | disclosed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-6355611-B1 | SODIUM SALT OF PROSTATE SPECIFIC ANTIGEN CONJUGATE COMPOUND; USEFUL IN TREATMENT OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2001030804-A2 | SALT FORM OF A CONJUGATE USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001029065-A1 | PROCESS FOR PREPARING PEPTIDE INTERMEDIATES | MERCK SHARP & DOHME LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028593-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030133927-A1 | Conjugates useful in the treatment of prostate cancer | BCL2, BCL2L10, BCL2L13 | PNMT 1126/4885NPC1 4614/4885RAB9A 3932/4885 |
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | PNMT 680/4885NPC1 1288/4885RAB9A 4133/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | PNMT 750/4885NPC1 1879/4885RAB9A 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.